Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Background: Sub-anesthetic ketamine administration may be helpful for substance use disorders. Converging evidence suggests that the efficacy of ketamine for certain conditions may implicate a subset of its psychoactive effects. Aims: The aim of this analysis is to evaluate whether the mystical-type effects of ketamine are critical for clinical efficacy in alcohol-dependent individuals. In this secondary analysis, we determine if a subset of the psychoactive effects of ketamine, the so-called mystical-type experience, mediates the effect of ketamine, when combined with motivational enhancement therapy, on at-risk drinking behavior in alcohol-dependent individuals interested in treatment. Methods: Forty alcohol dependent adults were randomized to either a 52-minute infusion of ketamine or midazolam, which they received on a designated quit-day during the second week of a five-week motivational enhancement therapy regimen. Psychoactive effects were assessed following the infusion, and alcohol use was monitored for the subsequent 3 weeks at each twice-weekly visit. Results: We found that ketamine leads to significantly greater mystical-type effects (by Hood Mysticism Scale) and dissociation (by Clinician Administered Dissociative States Scale) compared to the active control. Ketamine also led to significant reduction in at-risk drinking. The Hood Mysticism Scale, but not Clinician Administered Dissociative States Scale score, was found to mediate the effect of ketamine on drinking behavior. Conclusions: This trial adds evidence to the literature on the importance of mystical-type experiences in addiction treatment. Future research should continue to investigate the relationship between the psychoactive effects of psychedelic therapeutics and clinical outcomes for other substance use and mental health disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Findings from clinical studies on ketamine for the treatment of addiction support the notion that spiritual (Krupitsky and Grinenko, 1997) or mystical-type experiences (Rothberg et al., 2021;Dakwar et al., 2018) may also mediate its therapeutic effect.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Rothberg et al., 2021
Citations
Cites
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…and Schatzberg, 2015), possible neural mechanisms include the promotion of neurogenesis, dampened functional connectivity, sustained default-mode network attenuation, and glutamate modulation (Duman et al., 2012; Li et al., 2010; Maeng et al., 2008; Scheidegger et al., 2012; Zanos et al., 2016).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…ketamine-occa-sioned mystical-type experience in cocaine-dependent research volunteers engaged in human laboratory studies, as well as on studies investigating psilocybin for end-of-life anxiety and tobacco dependence (Dakwar et al., 2014b, 2018; Garcia-Romeu et al., 2014; Griffiths et al., 2016).”
BackgroundHettema, J., Steele, J., & Miller, W. R. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143833 · Cited by 1,803
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 3×
“The mystical-type effects of serotonergic hallucinogens, such as psilocybin, have also been shown to predict a positive response in diverse psychiatric and healthy populations (Garcia-Romeu et al., 2014; Griffiths et al., 2006, 2008; MacLean et al., 2011).”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Applied Survival Analysis: Regression Modeling of Time‐to‐Event Data
Hosmer, D. W., Lemeshow, S., & May, S. (2008) · Wiley Series in Probability and Statistics · doi:10.1002/9780470258019 · Cited by 1,298 · cited 2×
“To examine whether increases in HMS and/or CADSS scores predicted longer time to relapse and to examine the full mediation model with treatment group, HMS, and CADSS, Cox proportional hazard models were used (Hosmer et al., 2008).”
MethodHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · cited 1×
“…natural and synthetic substances that similarly induce neural and perceptual shifts in consciousness via different biological mechanisms, such as ketamine, ibogaine, or Salvia divinorum , are also often included in the category of psych-edelics (Bogenschutz and Pommy, 2012; Johnson et al., 2008).”
Background2010 National and State Costs of Excessive Alcohol Consumption
Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer, R. D. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.05.031 · Cited by 1,180 · cited 1×
“Alcohol misuse is a significant problem in the USA, with severe medical, psychological, and economic consequences to both individuals and society at large (Centers for Disease Control and Prevention, 2013; National Highway Traffic Safety Administration, 2017; Sacks et al., 2015; Substance Abuse and Mental Health Servi…”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“…of older trials, for LSD (Krebs and Johansen, 2012); small pilot studies or observational studies for psilocybin, ketamine, and ayahuasca (Bogenschutz et al, 2015; Grob et al., 1996; Krupitsky and Grinenko, 1997; Thomas et al., 2013); and a proof-of-concept randomized controlled trial of…”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 1×
“The current standard of care for alcohol use disorder (AUD) treatment includes both behavioral health interventions and medication treatment (De Sousa, 2010; Jonas et al., 2014; Kranzler and Kirk, 2001; McHugh et al., 2010), but effects are modest (De Sousa, 2010; Moos and Moos, 2006).”
BackgroundGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · cited 3×
“The mystical-type effects of serotonergic hallucinogens, such as psilocybin, have also been shown to predict a positive response in diverse psychiatric and healthy populations (Garcia-Romeu et al., 2014; Griffiths et al., 2006, 2008; MacLean et al., 2011).”
BackgroundMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895 · cited 3×
“The mystical-type effects of serotonergic hallucinogens, such as psilocybin, have also been shown to predict a positive response in diverse psychiatric and healthy populations (Garcia-Romeu et al., 2014; Griffiths et al., 2006, 2008; MacLean et al., 2011).”
BackgroundBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 1×
“Dissociative experiences were assessed via the CADSS, which is a 27-item inventory assessing for depersonalization, derealization, psychic fragmentation, and other dissociative states (Bremner et al., 1998). subject-rates scores.”
MethodThe Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · cited 1×
“Psychedelics are broadly defined as substances that produce shifts in consciousness comparable to trance, meditation, mystical experience, and other non-ordinary experiences (Borgonovi, 2014; Carhart-Harris and Goodwin, 2017; Escohotado, 1999).”
BackgroundThe Construction and Preliminary Validation of a Measure of Reported Mystical Experience
Hood, R. W. (1975) · Journal for the Scientific Study of Religion · doi:10.2307/1384454 · Cited by 703 · cited 2×
“The eight dimensions of mystical experience are represented by eight subscales on the HMS: ego quality (E), unifying quality (U), inner subjective quality (Is), temporal/spatial quality (T), noetic quality (N), inef-fability (I), positive affect (P), and religious quality (R) (Hood, 1975).”
BackgroundMethodRates and predictors of relapse after natural and treated remission from alcohol use disorders
Moos, R. H., & Moos, B. S. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01310.x · Cited by 601 · cited 1×
“The current standard of care for alcohol use disorder (AUD) treatment includes both behavioral health interventions and medication treatment (De Sousa, 2010; Jonas et al., 2014; Kranzler and Kirk, 2001; McHugh et al., 2010), but effects are modest (De Sousa, 2010; Moos and Moos, 2006).”
BackgroundLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537 · cited 1×
“…and Schatzberg, 2015), possible neural mechanisms include the promotion of neurogenesis, dampened functional connectivity, sustained default-mode network attenuation, and glutamate modulation (Duman et al., 2012; Li et al., 2010; Maeng et al., 2008; Scheidegger et al., 2012; Zanos et al., 2016).”
BackgroundPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476 · cited 2×
“The mystical-type effects of serotonergic hallucinogens, such as psilocybin, have also been shown to predict a positive response in diverse psychiatric and healthy populations (Garcia-Romeu et al., 2014; Griffiths et al., 2006, 2008; MacLean et al., 2011).”
BackgroundMotivational interviewing for substance abuse
Smedslund, G., Berg, R. C., Hammerstrøm, K. T., Steiro, A., Leiknes, K. A., Dahl, H. M., & Karlsen, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008063.pub2 · Cited by 408 · cited 1×
“MET aims at eliciting “change talk” from participants, and at helping them reflect on the goals they wish to achieve, as well as the steps they need to take (Hettema et al., 2005; Smedslund et al., 2011).”
BackgroundMacLean, K. A., Leoutsakos, J. S., Johnson, M. W., & Griffiths, R. R. (2012) · Journal for the Scientific Study of Religion · doi:10.1111/j.1468-5906.2012.01685.x · Cited by 405 · cited 1×
“…spiritual experience (Bogenschutz and Pommy, 2012), and encompass many of the same phenomena, including a sense of peace and joy, unity, sacredness, ineffability, a sense of transcending space and time, and an experience of tapping into some more universal aspect of reality (MacLean et al., 2012).”
BackgroundEfficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390 · cited 1×
“The current standard of care for alcohol use disorder (AUD) treatment includes both behavioral health interventions and medication treatment (De Sousa, 2010; Jonas et al., 2014; Kranzler and Kirk, 2001; McHugh et al., 2010), but effects are modest (De Sousa, 2010; Moos and Moos, 2006).”
BackgroundGale, R. M. (1960) · The Journal of Philosophy · doi:10.2307/2023665 · Cited by 352
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339 · cited 1×
“For example, alterations in default-mode network (DMN) connectivity induced by psilocybin administration were found to be correlated with mystical experiences (Lebedev et al., 2015), might be sustained after a single dose of ketamine (Scheidegger et al., 2012) and may have therapeutic relevance.”
BackgroundHuman psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Thomas, G., Lucas, P., Capler, N., Tupper, K., & Martin, G. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990003 · Cited by 330
Designing Experiments and Analyzing Data
Maxwell, S. E., Delaney, H. D., & Kelley, K. (2017) · Routledge eBooks · doi:10.4324/9781003476252 · Cited by 317
Scheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., & Seifritz, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044799 · Cited by 282 · cited 2×
“…and Schatzberg, 2015), possible neural mechanisms include the promotion of neurogenesis, dampened functional connectivity, sustained default-mode network attenuation, and glutamate modulation (Duman et al., 2012; Li et al., 2010; Maeng et al., 2008; Scheidegger et al., 2012; Zanos et al., 2016).”
BackgroundSpirituality, mindfulness and substance abuse
Leigh, J., Bowen, S., & Marlatt, G. A. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.01.010 · Cited by 282 · cited 1×
“…an association between spirituality and fewer relapses and longer-term recovery, as well as detected a negative correlation with frequent binge-drinking (Carter, 1998; Kaskutas et al., 2003; Kelly et al., 2011; Leigh et al., 2005; Miller and Saunders, 2011; Robinson et al., 2007; Zemore, 2007).”
BackgroundThe phenomenon of quantum change
Miller, W. R. (2004) · Journal of Clinical Psychology · doi:10.1002/jclp.20000 · Cited by 272 · cited 1×
“These existential mechanisms include a refreshed sense of self, others, and the world; a reap-praisal of values and commitments; and a new orientation towards life’s purpose and meaning (James, 1907; Miller, 2004; Miller and C’de Baca, 2001).”
BackgroundDelaney, C. (2005) · Journal of Holistic Nursing · doi:10.1177/0898010105276180 · Cited by 259 · cited 3×
“…exalted mode of being (such as “cos-mic consciousness” or Samadhi), or transcendent entity (e.g. God, spirit, or higher power); finding redemption from sin, or freedom from suffering; and deepening a personal identification with the interconnectedness of the world (Delaney, 2005; James, 1907).”
BackgroundKetamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246 · cited 4×
“Krupitsky was one of the first researchers to recognize that its psychoactive effects might be impactful (Krupitsky and Grinenko, 1997; Krupitsky et al., 2002).”
BackgroundResultInfluentialKetamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 3×
“Krupitsky was one of the first researchers to recognize that its psychoactive effects might be impactful (Krupitsky and Grinenko, 1997; Krupitsky et al., 2002).”
BackgroundResultKelly, J. F., Stout, R. L., Magill, M., Tonigan, J. S., & Pagano, M. E. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01362.x · Cited by 219 · cited 1×
“…an association between spirituality and fewer relapses and longer-term recovery, as well as detected a negative correlation with frequent binge-drinking (Carter, 1998; Kaskutas et al., 2003; Kelly et al., 2011; Leigh et al., 2005; Miller and Saunders, 2011; Robinson et al., 2007; Zemore, 2007).”
BackgroundIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201 · cited 1×
“While it remains unclear how ketamine exerts long-lasting beneficial effects on psychiatric and addicted populations (Dakwar et al., 2014a; Iadarola et al., 2015; Sanacora and Schatzberg, 2015), possible neural mechanisms include the promotion of neurogenesis, dampened functional connectivity,…”
BackgroundBoschloo, L., Vogelzangs, N., Smit, J. H., van den Brink, W., Veltman, D. J., Beekman, A. T. F., & Penninx, B. W. J. H. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.12.014 · Cited by 198
Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence
Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2007.10399860 · Cited by 183 · cited 1×
“…the possible impact of psychedelics on mental health issues, and on addiction and SUDs in particular (Dakwar et al., 2014a, 2017, 2018, 2020; Delaney, 2005; Ezquerra-Romano et al., 2018; Jones et al., 2018; Krupitsky and Grinenko, 1997; Krupitsky et al., 2002, 2007; Savage and McCabe, 1973).”
BackgroundDakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070684 · Cited by 183 · cited 8×
“…been a major resurgence of research examining the possible impact of psychedelics on mental health issues, and on addiction and SUDs in particular (Dakwar et al., 2014a, 2017, 2018, 2020; Delaney, 2005; Ezquerra-Romano et al., 2018; Jones et al., 2018; Krupitsky and Grinenko, 1997; Krupitsky et…”
BackgroundResultInfluentialSelf-citationQuantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives
VAILLANT, G. E. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1620 · Cited by 170
Ketamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163 · cited 2×
“In the last two decades, there has been a major resurgence of research examining the possible impact of psychedelics on mental health issues, and on addiction and SUDs in particular (Dakwar et al., 2014a, 2017, 2018, 2020; Delaney, 2005; Ezquerra-Romano et al., 2018; Jones et al., 2018; Krupitsky and Grinenko, 1997; K…”
BackgroundSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160 · cited 2×
“…unclear how ketamine exerts long-lasting beneficial effects on psychiatric and addicted populations (Dakwar et al., 2014a; Iadarola et al., 2015; Sanacora and Schatzberg, 2015), possible neural mechanisms include the promotion of neurogenesis, dampened functional connectivity, sustained…”
BackgroundA Role for Spiritual Change in the Benefits of 12‐Step Involvement
Zemore, S. E. (2007) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00499.x · Cited by 155 · cited 2×
“…the possible impact of psychedelics on mental health issues, and on addiction and SUDs in particular (Dakwar et al., 2014a, 2017, 2018, 2020; Delaney, 2005; Ezquerra-Romano et al., 2018; Jones et al., 2018; Krupitsky and Grinenko, 1997; Krupitsky et al., 2002, 2007; Savage and McCabe, 1973).”
BackgroundSix-Month Changes in Spirituality, Religiousness, and Heavy Drinking in a Treatment-Seeking Sample*
Robinson, E. A. R., Cranford, J. A., Webb, J. R., & Brower, K. J. (2007) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2007.68.282 · Cited by 149
Residential Psychedelic (LSD) Therapy for the Narcotic Addict: A Controlled Study
Savage, C. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750360040005 · Cited by 148 · cited 1×
“…the possible impact of psychedelics on mental health issues, and on addiction and SUDs in particular (Dakwar et al., 2014a, 2017, 2018, 2020; Delaney, 2005; Ezquerra-Romano et al., 2018; Jones et al., 2018; Krupitsky and Grinenko, 1997; Krupitsky et al., 2002, 2007; Savage and McCabe, 1973).”
BackgroundDakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143
Self-citationThe Role of Religion, Spirituality and Alcoholics Anonymous in Sustained Sobriety
Kaskutas, L. A., Kaskutas, L. A., Bond, J., & Weisner, C. (2003) · Alcoholism Treatment Quarterly · doi:10.1300/j020v21n01_01 · Cited by 137
Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., & Back, S. E. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00277 · Cited by 135 · cited 1×
“…the possible impact of psychedelics on mental health issues, and on addiction and SUDs in particular (Dakwar et al., 2014a, 2017, 2018, 2020; Delaney, 2005; Ezquerra-Romano et al., 2018; Jones et al., 2018; Krupitsky and Grinenko, 1997; Krupitsky et al., 2002, 2007; Savage and McCabe, 1973).”
BackgroundBogenschutz, M. P., & Pommy, J. M. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1376 · Cited by 125
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123 · cited 8×
“Accordingly, infusion-dependent mystical-type effects have been found to mediate the effects of ketamine on motivation to quit drug use, and on drug use and craving, in two human laboratory studies with cocaine-dependent volunteers (Dakwar et al., 2014b, 2018).”
BackgroundResultInfluentialSelf-citationDakwar, E., Hart, C. L., Levin, F. R., Nunes, E. V., & Foltin, R. W. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.39 · Cited by 105 · cited 1×
“…been a major resurgence of research examining the possible impact of psychedelics on mental health issues, and on addiction and SUDs in particular (Dakwar et al., 2014a, 2017, 2018, 2020; Delaney, 2005; Ezquerra-Romano et al., 2018; Jones et al., 2018; Krupitsky and Grinenko, 1997; Krupitsky et…”
BackgroundSelf-citationDakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., & Levin, F. R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.005 · Cited by 85
Self-citationLuckenbaugh, D. A., Ibrahim, L., Brutsche, N., Franco‐Chaves, J., Mathews, D., Marquardt, C. A., Cassarly, C., & Zarate, C. A. (2012) · Bipolar Disorders · doi:10.1111/bdi.12003 · Cited by 68 · cited 10×
“LSD, psilocybin, ayahuasca, and ketamine may decrease alcohol misuse and cravings in those with AUDs, according to a meta-analysis of older trials, for LSD (Krebs and Johansen, 2012); small pilot studies or observational studies for psilocybin, ketamine, and ayahuasca (Bogenschutz et al, 2015; Grob et al., 1996; Krupi…”
BackgroundInfluentialThe effects of spiritual practices on recovery from substance abuse
Carter (1998) · Journal of Psychiatric and Mental Health Nursing · doi:10.1046/j.1365-2850.1998.00153.x · Cited by 52 · cited 1×
“…an association between spirituality and fewer relapses and longer-term recovery, as well as detected a negative correlation with frequent binge-drinking (Carter, 1998; Kaskutas et al., 2003; Kelly et al., 2011; Leigh et al., 2005; Miller and Saunders, 2011; Robinson et al., 2007; Zemore, 2007).”
BackgroundThe Pharmacotherapy of Alcohol Dependence: A State of the Art Review
Sousa, A. D. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58820 · Cited by 32
Miller, M. L., & Saunders, S. M. (2011) · Psychology of Addictive Behaviors · doi:10.1037/a0022224 · Cited by 10 · cited 1×
“…an association between spirituality and fewer relapses and longer-term recovery, as well as detected a negative correlation with frequent binge-drinking (Carter, 1998; Kaskutas et al., 2003; Kelly et al., 2011; Leigh et al., 2005; Miller and Saunders, 2011; Robinson et al., 2007; Zemore, 2007).”
BackgroundMaltbie, E. A., Gopinath, K., & Howell, L. L. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05204-4 · Cited by 7 · cited 1×
“Interestingly, these mood-enhancing effects may be more pronounced in individuals with a family history of AUD (Luckenbaugh et al., 2012; Maltbie et al., 2019); a majority of our participants had a first-degree family history of alcoholism (Dakwar et al., 2020), perhaps rendering them more…”
BackgroundDesigning Experiments and Analyzing Data
Maxwell, S. E., Delaney, H. D., & Kelley, K. (2017) · doi:10.4324/9781315642956
Research works printed but not linked: 7
- Borgonovi R, 2014, Aldous Huxley Annual, 12, 72
- Burns L, 2002, J Trauma Stress, 68, 299
- Centers for Disease Control and Prevention (CDC), 2013, Alcohol Related Disease Impact (ARDI) Application
- Escohotado A, 1999, A Brief History of Drugs: From the Stone Age to the Stoned Age, 114
- McHugh RK, 2010, Psychiatr Clin, 33, 511
- National Highway Traffic Safety Administration, 2017, Traffic Safety Facts: Alcohol-Impaired Driving, 1
- Pahnke WN, 1966, Int J Parapsychol, 8, 295
Cited by
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
“Our search identified 2 papers investigating the efficacy of TIMBER on a single sample in the context of a RCT (Pradhan et al., 2017, 2018).”
BackgroundInfluentialKohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
“1 3 by the psychoactive profile of the drug have been suggested to be important [86].”
BackgroundSchimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
“Findings from clinical studies on ketamine for the treatment of addiction support the notion that spiritual (Krupitsky and Grinenko, 1997) or mystical-type experiences (Rothberg et al., 2021; Dakwar et al., 2018) may also mediate its therapeutic effect.”
BackgroundMartinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Di Carlo, F., D’Andrea, G., Collevecchio, R., Di Muzio, I., Sensi, S. L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11070856 · Cited by 111
“Patients were mostly diagnosed with OCD [13,40,45,47,55,56,60–64] or a SUD, such as opioid dependence [41,43–46,57–59], cocaine dependence [49,50,52,66–68] or alcohol dependence [51,54,65].”
Background
Metadata
- Authors
- Rothberg, R. L., Azhari, N., Haug, N. A., & Dakwar, E.
- Affiliations
- Palo Alto University (US)
- Columbia University Irving Medical Center (US)
- Corresponding author
- Dakwar, Elias
- ORCID
- Rothberg, Rebecca L
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-12-13
- Volume
- 35
- Issue
- 2
- Pages
- 150-158
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3111975240
- Cited by
- 97
- References
- 59
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 25 · 2023: 12 · 2022: 19 · 2021: 8
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (AA023010)
- National Institute on Drug Abuse (DA031771)
- New York State Psychiatric Institute
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- ketamine, hazardous drinking, alcoholism, motivational enhancement therapy, dissociation, psychoactive effects, mediation, midazolam, alcoholism treatment
- MeSH terms
- Alcohol Drinking, Dissociative Disorders, Double-Blind Method, Female, Hallucinogens, Humans, Ketamine, Male, Midazolam, Middle Aged, Mysticism, Surveys and Questionnaires, Behavior, Addictive, Treatment Outcome, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.